Liver Failure
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age range from 18 to 65 years old; 2. Patients with acute liver failure in the early and intermediate stages caused by various reasons; 3. Total bilirubin (TBil) >= 171µmol/L or an increase of = 17.1µmol/L per day; 4. Prothrombin activity (PTA) between 20% and 40% (or INR between 1.5 and 2.6); 5. No hepatic encephalopathy or encephalopathy below grade II (including grade II); 6. Elevated inflammatory markers (IL-6 / TNF-a / CRP, etc.); 7. The subjects are able to communicate well with the researchers and can complete the study in accordance with the study regulations; 8. The subjects must be informed of this study and voluntarily sign a written informed consent form before the experiment.
Exclusion criteria
Exclusion criteria: 1.Patients with severe active bleeding or diffuse intravascular coagulation; 2.Patients with a high degree of allergy to blood products or drugs used during treatment, such as plasma, heparin, and protamine; 3.Patients with circulatory failure; 4.Patients with a MELD score > 30; 5.Patients with other severe heart diseases, lung diseases, blood diseases, autoimmune diseases, or diabetes; 6.Subjects who may be unable to complete this study for other reasons or who the researchers believe should not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival rate at 4 weeks after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| conversion rate to liver transplantation;Liver disease score(MELD, MELD-Na, Child-Pugh, COSSH-ACLF ?s);Inflammatory(IL-6, TNF-a, CRP);Liver disease indicators(PTA, lactic aicd, blood ammonia, AFP, ferritin);Survival rate at 7days, 14days, 8 weeks and 12 weeks after treatment; | — |
Countries
China
Contacts
ZhuJiang Hospital of Southern Medical University